



(51) International Patent Classification:

A61K 31/4745 (2006.01) A61N 5/00 (2006.01)
A61K 41/00 (2020.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2024/075613

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/582,280 13 September 2023 (13.09.2023) US
63/582,283 13 September 2023 (13.09.2023) US
63/564,659 13 March 2024 (13.03.2024) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 15185
SÖDERTÄLJE (SE).

(72) Inventors: **KARANOVIC, Djuro**; 1800 Concord Pike,
P.O. Box 15437, Wilmington, Delaware 19850-5437 (US).
GLOVER, Colin Paul Jonathan; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).
POLANSKA, Urszula Maria; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).
STAVRAKA, Chara; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA (GB).
TRIGG, William John; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2

0AA (GB). **FAN, Chunling**; 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US).
MUNDIN, Gillian Elizabeth; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA
(GB). **HAMERLINK, Petra**; 1 Francis Crick Avenue,
Cambridge Biomedical Campus, Cambridge CB2 0AA
(GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip,
Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: AZD1390, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN COMBINATION WITH RADIATION
FOR USE IN A METHOD OF TREATMENT OF A CNS TUMOUR




FIG. 1

(57) Abstract: AZD1390, or a pharmaceutically acceptable salt thereof, for use in a method of treatment of a CNS tumour, wherein said treatment comprises the separate, sequential or simultaneous administration of i) a total daily dose of about 300 mg of said AZD1390, optionally in the form of a pharmaceutically acceptable salt thereof, and ii) radiation therapy, to said subject.

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*